GlassScriptPhysician profile
Ronald D Sanzone
NPI 1457393381
$3,705.02
in general payments reported to CMS, 2019-2025
24 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $390 · 2021: $305 · 2022: $519 · 2023: $776 · 2024: $199 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,026.27 | 2019-2023 | Watchman Access System, Watchman Flx |
| Edwards Lifesciences Corporation | $476.59 | 2022-2023 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $471.38 | 2019-2023 | Wegovy |
| Abbvie INC. | $311.45 | 2019-2025 | Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $249.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $212.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $129.98 | 2022 | |
| Glaxosmithkline, LLC. | $124.98 | 2019-2023 | Shingrix, Bexsero, Arexvy |
| Heartflow, INC. | $121.76 | 2025 | |
| Merck Sharp & Dohme LLC | $92.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $80.45 | 2019-2020 | |
| Hologic Sales and Service, LLC | $74.46 | 2024 | Aptima |
| Medtronic, INC. | $50.00 | 2023 | Onyx Frontier |
| Daiichi Sankyo INC. | $36.78 | 2019 | |
| Strongbridge US INC. | $34.37 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33.43 | 2019 | |
| Currax Pharmaceuticals LLC | $29.65 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.91 | 2021 | |
| Amgen INC. | $25.91 | 2020 | |
| Amarin Pharma, INC. | $24.58 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.51 | 2019 | |
| Phadia US INC. | $16.05 | 2019 | |
| Sanofi Pasteur INC. | $15.80 | 2019 | |
| Lilly USA, LLC | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Sanzone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.